Session » Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster I
- 10:30AM-12:30PM
-
Abstract Number: 0343
An Interlaboratory Variability Study of Detection Methods for Myositis-Specific and Myositis-Associated Autoantibodies in Sera from Patients with Idiopathic Inflammatory Myopathies
- 10:30AM-12:30PM
-
Abstract Number: 0335
Analysis of the Prevalence of Diabetes Mellitus in Patients with Adult-onset Dermatomyositis
- 10:30AM-12:30PM
-
Abstract Number: 0338
Anti-MDA5 Antibody-positive Dermatomyositis Associated Interstitial Lung Disease – Survival Benefit of Treatment with Rituximab, Janus Kinase Inhibitor and Glucocorticoid Combination in a Prospective Cohort
- 10:30AM-12:30PM
-
Abstract Number: 0330
Baseline Interstitial Lung Disease (ILD) Characteristics and Outcomes in Patients with Anti-synthetase Syndrome Related ILD (ASSD-ILD): Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
- 10:30AM-12:30PM
-
Abstract Number: 0331
Cardiac Manifestations in Patients with Anti-Synthetase Syndrome: Analysis from the “Classification Criteria for Anti-synthetase Syndrome (CLASS)” Project Database
- 10:30AM-12:30PM
-
Abstract Number: 0344
Characteristics of Patients with Antisynthetase Antibodies
- 10:30AM-12:30PM
-
Abstract Number: 0337
Characterization of Statin Induced Myopathy in the Hospital Setting
- 10:30AM-12:30PM
-
Abstract Number: 0327
Clinical and Immunological Risk Factors Associated with Fybromialgia in Patients with Idiopathic Inflammatory Myopathies
- 10:30AM-12:30PM
-
Abstract Number: 0339
Clinical Characteristics Associated with Inpatient Mortality in Dermatomyositis Patients: A Single Center Retrospective Cohort Study
- 10:30AM-12:30PM
-
Abstract Number: 0346
Clonally Expanded and Total B Cells in Patients with Idiopathic Inflammatory Myopathies Show Skewed B Cell Subset Distribution and Reduced Somatic Hypermutation Relative to Healthy Controls
- 10:30AM-12:30PM
-
Abstract Number: 0320
Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis
- 10:30AM-12:30PM
-
Abstract Number: 0324
Correlative Studies of CABA-201, a Fully Human, Autologous 4-1BB Anti-CD19 CAR T Cell Therapy in Patients with Immune-Mediated Necrotizing Myopathy and Systemic Lupus Erythematosus from the RESET-MyositisTM and RESET-SLETM Clinical Trials
- 10:30AM-12:30PM
-
Abstract Number: 0347
Dermato-polymyositis Mortality in U.S. Population: Declining Cancer and Cardiovascular Diseases Among the Leading Underlying Causes of Death over Two Decades
- 10:30AM-12:30PM
-
Abstract Number: 0321
Diffusion Weighted Imaging in Muscle MRI Can Detect Quantitative Improvements in Muscle Edema: A Post-hoc Analyses of the Study of Tofacitinib in Refractory Dermatomyositis
- 10:30AM-12:30PM
-
Abstract Number: 0341
Efficacy and Safety of Nintedanib in Patients with Idiopathic Inflammatory Myopathy-related Interstitial Lung Disease
- 10:30AM-12:30PM
-
Abstract Number: 0322
Enhanced Detection of Myocarditis in Idiopathic Inflammatory Myopathies Utilizing Multiparametric Cardiac Magnetic Resonance Imaging
- 10:30AM-12:30PM
-
Abstract Number: 0328
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
- 10:30AM-12:30PM
-
Abstract Number: 0342
Measurement of Serum Cytokine and Chemokine Level to Predict Poor Treatment Response in Patients with Idiopathic Inflammatory Myositis
- 10:30AM-12:30PM
-
Abstract Number: 0336
Mortality: Comparison, Causes and Determinants in Subgroups of Idiopathic Inflammatory Myopathies
- 10:30AM-12:30PM
-
Abstract Number: 0334
Normal Creatine Kinase in Idiopathic Inflammatory Myopathies- Patient Characteristics and Disease Activity
- 10:30AM-12:30PM
-
Abstract Number: 0323
Pain Prevalence and Factors Associated with Pain Levels in Patients with Idiopathic Inflammatory Myopathies
- 10:30AM-12:30PM
-
Abstract Number: 0332
Predictors of Long-term Radiographic Changes in Patients with Idiopathic Inflammatory Myopathies Using Quantitative Imaging Analysis: Real World Experience from a Single Center Longitudinal Cohort
- 10:30AM-12:30PM
-
Abstract Number: 0333
Predictors of Transplant-Free Survival in Idiopathic Inflammatory Myopathies- associated Interstitial Lung Disease
- 10:30AM-12:30PM
-
Abstract Number: 0340
Progressive Pulmonary Fibrosis Predicts Mortality in Myositis-Associated Interstitial Lung Disease
- 10:30AM-12:30PM
-
Abstract Number: 0329
Racial, Ethnic, Sex, and Geographical Diversity in Myositis Clinical Trials: Future Steps for Equitable Representation by the MIHRA Global Equity and Clinical Trial Readiness Cores
- 10:30AM-12:30PM
-
Abstract Number: 0319
Sporadic Inclusion Body Myositis Novel Autoantibody and Biomarker Research Utilizing Proteome Microarray and Mass Spectrometry Proteomics Analysis
- 10:30AM-12:30PM
-
Abstract Number: 0325
The Impact of Polymyositis and Dermatomyositis in Patients Hospitalized with Inflammatory Bowel Disease: A Nationwide Inpatient Database Analysis
- 10:30AM-12:30PM
-
Abstract Number: 0345
Treatment Patterns and Glucocorticoid Burden of Dermatomyositis Patients: A Cohort Study in the University of Pittsburgh’s Myositis Registry
- 10:30AM-12:30PM
-
Abstract Number: 0348
Upadacitinib in Interstitial Lung Disease Associated with Idiopathic Inflammatory Myopathies
- 10:30AM-12:30PM
-
Abstract Number: 0326
Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)